Flucytosine
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Flucytosine: From Invasive Fungal Infections to Bone Paget Disease
One-Sentence Summary
Flucytosine (DB01099) is an antifungal agent originally used for invasive fungal infections such as candidiasis and cryptococcosis, typically combined with amphotericin B. The TxGNN model predicts a possible effect on Bone Paget Disease with a very high similarity score, but this direction is currently supported by 0 clinical trials and 0 publications — it is a purely computational hypothesis with no independent validation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Invasive fungal infections (candidiasis, cryptococcosis) — based on known pharmacology; no India licensing record exists |
| Predicted New Indication | Bone Paget Disease |
| TxGNN Prediction Score | 99.04% |
| Evidence Level | L5 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacological information, Flucytosine is an antimetabolite antifungal: it is taken up by fungal cells and converted by fungal cytosine deaminase into 5-fluorouracil (5-FU), which is then incorporated into fungal RNA/DNA to block nucleic acid synthesis. It has no comparable conversion pathway in human cells at therapeutic doses (humans have minimal cytosine deaminase activity), and is used clinically — almost always in combination with amphotericin B — for invasive candidiasis and cryptococcal meningitis.
Bone Paget disease, in contrast, is a disorder of localized bone remodeling driven by abnormally activated osteoclasts, with standard treatment (bisphosphonates) targeting osteoclast-mediated bone resorption directly. There is no established biological pathway connecting fungal cytosine deaminase/5-FU metabolism to osteoclast regulation or bone turnover.
Given this, the very high TxGNN score most likely reflects knowledge-graph embedding similarity (e.g., shared graph neighbors or indirect relational patterns) rather than a demonstrable pharmacological mechanism. Without any supporting mechanistic, preclinical, or clinical evidence, this prediction should be treated as a low-confidence hypothesis rather than a plausible repurposing candidate.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
- Drug Interactions: 85 documented interactions on record. One Major interaction: Deferiprone. Numerous Moderate interactions, notably with nephrotoxic/renal-clearance-affecting agents that can raise Flucytosine levels and toxicity risk — Amphotericin B (conventional, lipid complex, liposomal, and cholesteryl sulfate formulations), Vancomycin, aminoglycosides (Kanamycin, Neomycin, Streptomycin), Polymyxin B, Bacitracin, Pentamidine, Deferasirox, and NSAIDs (Ibuprofen); also moderate interactions with 5-aminosalicylate agents (Mesalazine, Balsalazide, Olsalazine, Sulfasalazine) and radiopharmaceuticals (Iobenguane I-131, Strontium chloride Sr-89).
No safety data is available for warnings or contraindications in this evidence pack; please refer to the package insert for that information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction relies solely on a TxGNN model score (Evidence Level L5) with zero supporting clinical trials or literature, no established mechanistic link between antifungal 5-FU metabolism and osteoclast-driven bone pathology, a blocking gap in TFDA/local labeling data, and a drug that is not currently marketed in India. Combined with a substantial drug-interaction burden (85 interactions, including one Major), the current evidence does not justify moving beyond initial screening.
To proceed, the following is needed:
- Resolve DG001 (TFDA label/warnings and contraindications) — currently blocking safety assessment
- Confirm original MOA via DrugBank (DG002) to properly evaluate mechanistic plausibility
- Independent preclinical or mechanistic rationale linking cytosine deaminase/5-FU pathway to osteoclast biology or bone turnover
- At minimum, case-report or in-vitro evidence before any further investment in this indication
- Full renal-function-based DDI risk assessment given Flucytosine’s narrow therapeutic index and interaction profile
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.